Looking for Blood Clots in the Heart in People With Cardiac Amyloidosis
Uses contrast heart CT scans to check for clots in adults with cardiac amyloidosis.
Plain-language title generated from the registry record
Registry title: Prevalence of Cardiac Thrombi in Cardiac Amyloidosis
Key facts
- Where
- Dijon, FranceSee the site
Where in France
- Chu Dijon BourogneDijon, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Trial code
- NCT07648303
- Record updated
- 17 September 2026
- Original description
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in elderly patients), leading to heart failure and arrhythmias. More than 98% of currently diagnosed cases of cardiac amyloidosis result from fibrils composed of monoclonal immunoglobulin light chains (AL) or transthyretin (ATTR), in its hereditary (ATTRv) or acquired (ATTRwt) form.Read full original descriptionShow less
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in elderly patients), leading to heart failure and arrhythmias. More than 98% of currently diagnosed cases of cardiac amyloidosis result from fibrils composed of monoclonal immunoglobulin light chains (AL) or transthyretin (ATTR), in its hereditary (ATTRv) or acquired (ATTRwt) form.
Its prevalence is rising sharply due to an aging population and improved diagnostic techniques. Atrial fibrillation is responsible, in particular, for heart failure, arrhythmias, conduction disorders, and ischemic strokes, and is associated with significant morbidity and mortality. These patients have a much higher-than-normal risk of stroke because they are in a procoagulant state in the left atrium, even in the absence of atrial fibrillation. Intracardiac thrombi (ICTs) are present in 28% of patients with AC requiring cardioversion, compared with 2.5% of patients without AC, 50% of whom are on anticoagulants.
It has also been shown that the CHA2DS2-VASc score is not effective in predicting thromboembolic risk, and that direct oral anticoagulants (DOACs) are as effective as vitamin K antagonists (VKAs) in preventing embolisms.
The prevalence and factors associated with the development of intracardiac thrombi in patients with cardiac amyloidosis are unknown, as the available retrospective studies focused only on selected high-risk patients. Furthermore, tafamidis is now available to stabilize the course of cardiac amyloidosis and improve prognosis, but its effect on thromboembolic risk remains unknown.
Inclusion: Individuals with a diagnosis of cardiac amyloidosis (AL diagnosed by echocardiography and/or MRI combined with histological evidence; or ATTR diagnosed in the presence of typical cardiac abnormalities on echocardiography and/or MRI with cardiac hyperintensity); Individuals who have had at least one consultation related to their cardiac amyloidosis at the Dijon University Hospital during the year prior to enrollment; Adults.
Exclusion: Anyone with a known allergy to iodinated contrast agents; Individuals with a known history of cardiac thrombus; Individuals with a history of percutaneous or surgical closure of the left atrial appendage; Individuals with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²; Overt thyrotoxicosis; Uncontrolled asthma; Individuals not enrolled in or not eligible for a social security program; Individuals under legal guardianship; Individuals under conservatorship; Pregnant or breastfeeding women.